中国临床保健杂志2017，Vol.20Issue(1)：67-70,4.DOI:10.3969/J.issn.1672-6790.2017.01.021
西格列汀与格列齐特缓释片联用甘精胰岛素治疗2型糖尿病的疗效与安全性评价
Comparison of the efficacy and safety of the sitagliptin plus glargine insulin or the gliclazide plus glargine insu-lin in patients with type 2 diabetes
摘要
Abstract
Objective To investigate the efficacy and safety of the sitagliptin plus glargine insulin or the glicla-zide plus glargine insulin in patients with type 2 diabetes.Methods Eighty-three patients with type 2 diabetes were randomly assigned to 2 group.The observation group was treated with sitagliptin plus glargine insulin,and control group was treated with gliclazide plus glargine insulin.The duration of treatment was 1 6 weeks.FPG,2hPG,HbA1 c,FIns, HOMA-IR,BMI,insulin dosage and adverse events were recorded.Results Glycemic control was improved in both groups.FPG,2hPG,HbA1 c,HOMA-IR were significantly decreased compared to pretreatment,FIns were significantly in-creased(P <0.05),FPG in control group were lower than those in observation group(P <0.05),but 2hPG in observa-tion group were lower than those in control group(P <0.05);HbA1 c targeting rate,HOMA-IR between the two groups had no significant difference.But the BMI level in observation group down by 6.25% compared with control group,also the insulin dose was reduced by 12.92%,the difference was statistically significant.There was significant difference be-tween observation group(2.38%)and control group(9.76%)in the proportion of hypoglycemia too.Conclusion Sita-gliptin combined with glargine had better effect safety in the treatment of type 2 diabetes.关键词
糖尿病,2 型/格列齐特/二肽基肽酶Ⅳ抑制剂Key words
Diabetes mellitus,type 2/Gliclazide/Dipeptidyl-peptidase IV inhibitors分类
医药卫生引用本文复制引用
张丹丹,李会英,毛玉山,吴伦,黄静..西格列汀与格列齐特缓释片联用甘精胰岛素治疗2型糖尿病的疗效与安全性评价[J].中国临床保健杂志,2017,20(1):67-70,4.基金项目
宁波大学校级科研项目 （）
